Introduction The scale of the COVID-19 vaccine program, and appropriate focus on older
individuals, emphasised monitoring of mortality as an important part of COVID-19 vaccine …

Introduction Understanding background incident rates of adverse events following
immunisation (AEFI) is essential to rapidly detect, evaluate, respond to, and communicate …

Introduction Nuvaxovid became available in Australia from February 2022, a year after the
first COVID-19 vaccines. This protein-based vaccine was an alternative for people who had …

Safe vaccines are critical for biosecurity protection, yet adverse events—rightly or wrongly
attributed to immunization—potentially cause rapid loss of confidence, reduced vaccine …

The COVID-19 pandemic necessitated an urgent global response in vaccine deployment,
achieving over 70.6% global vaccination coverage with at least one dose. This study …

Objective Post-licensure vaccine safety surveillance of adverse events following
immunisation is critical to ensure public safety and confidence in vaccines. This paper aims …

Introduction Nuvaxovid became available in Australia from February 2022, a year later than
the first COVID-19 vaccines were released. It was a much-anticipated alternative vaccine for …

In Victoria, Australia, jurisdictional vaccine safety service is conducted by SAEFVIC
(Surveillance of Adverse Events Following Vaccination in the Community). SAEFVIC …